Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics

Biochemical Pharmacology

Volumn 80, Issue 7, 2010, Pages 1063-1074

  Li, Fei ^a   Patterson, Andrew D ^a   Höfer, Constance C ^b   Krausz, Kristopher W ^a   Gonzalez, Frank J ^a   Idle, Jeffrey R ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DMPKORE   (Germany)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cyclophosphamide; Ifosfamide; Metabolomics; Tandem mass spectrometry; Time of flight mass spectrometry; Ultra performance liquid chromatography

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; 4 OXOCYCLOPHOSPHAMIDE; ACETYLCYSTEINE DERIVATIVE; ACROLEIN; ALDOPHOSPHAMIDE; AZIRIDINE DERIVATIVE; CARBOCISTEINE; CHLOROACETALDEHYDE; CYCLOPHOSPHAMIDE; DICHLORODIETHYLAMINE; DRUG METABOLITE; GLYCOLIC ACID DERIVATIVE; HYDRACRYLIC ACID; IFOSFAMIDE; OXAZOLIDINE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PHOSPHORAMIDE MUSTARD; PIPERAZINE DERIVATIVE; ACETALDEHYDE; DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG METABOLISM; ELECTROSPRAY; MALE; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RING OPENING; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PROCEDURES;

ACETALDEHYDE; ANIMALS; CARBOCYSTEINE; CHROMATOGRAPHY, LIQUID; CYCLOPHOSPHAMIDE; IFOSFAMIDE; MALE; MASS SPECTROMETRY; METABOLOMICS; MICE; MICE, INBRED C57BL; PHARMACEUTICAL PREPARATIONS;

EID: 77955660756     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.06.002     Document Type: Article

References (67)

1. Druckrey H., Raabe S. Specific chemotherapy of carcinoma of the prostate. Klin Wochenschr 1952, 30:882-884.
2. Arnold H., Bourseaux F., Brock N. Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-ASTA) in experimental tumours of the rat. Nature 1958, 181:931.
3. Brock N., Hohorst H.J. Metabolism of cyclophosphamide. Cancer 1967, 20:900-904.
4. Sladek N.E. Evidence for an aldehyde possessing alkylating activity as the primary metabolite of cyclophosphamide. Cancer Res 1973, 33:651-658.
5. Hill D.L., Laster W.R., Struck R.F. Enzymatic metabolism of cyclophosphamide and nicotine and production of a toxic cyclophosphamide metabolite. Cancer Res 1972, 32:658-665.
6. Alarcon R.A., Meienhofer J. Formation of the cytotoxic aldehyde acrolein during In vitro degradation of cyclophosphamide. Nature New Biol 1971, 233:250-252.
7. Connors T.A., Cox P.J., Farmer P.B., Foster A.B., Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 1974, 23:115-129.
8. Colvin M., Padgett C.A., Fenselau C. A biologically active metabolite of cyclophosphamide. Cancer Res 1973, 33:915-918.
9. Struck R.F., Kirk M.C., Mellett L.B., el Dareer S., Hill D.L. Urinary metabolites of the antitumor agent cyclophosphamide. Mol Pharmacol 1971, 7:519-529.
10. Fenselau C., Lehman J.P., Myles A., Brandt J., Yost G.S., Friedman O.M., et al. Iminocyclophosphamide as a chemically reactive metabolite of cyclophosphamide. Drug Metab Dispos 1982, 10:636-640.
11. Struck R.F., Kirk M.C., Witt M.H., Laster W.R. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom 1975, 2:46-52.
12. Brock N. New nitrogen mustard phosphamide esters and their cytostatic activity. Laval Med 1968, 39:696-701.
13. Alarcon R.A., Meienhofer J., Atherton E. Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide. Cancer Res 1972, 32:2519-2523.
14. Dirven H.A., Megens L., Oudshoorn M.J., Dingemanse M.A., van Ommen B., van Bladeren P.J. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem Res Toxicol 1995, 8:979-986.
15. Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 1976, 60:437-443.
16. Goren M.P., Wright R.K., Pratt C.B., Pell F.E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986, 2:1219-1220.
17. Highley M.S., Momerency G., Van Cauwenberghe K., Van Oosterom A.T., de Bruijn E.A., Maes R.A., et al. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab Dispos 1995, 23:433-437.
18. Norpoth K., Raidt H., Witting U., Muller G., Norpoth R. Side chain oxidation of ifosfamide in man. Klin Wochenschr 1975, 53:1075-1076.
19. Shaw I.C., Graham M.I., McLean A.E. 2-Chloroacetaldehyde: a metabolite of cyclophosphamide in the rat. Cancer Treat Rev 1983, 10(Suppl. A):17-24.
20. Shaw I.C., Graham M.I., McLean A.E. 2-Chloroacetaldehyde, a metabolite of cyclophosphamide in the rat. Xenobiotica 1983, 13:433-437.
21. Boddy A.V., Yule S.M., Wyllie R., Price L., Pearson A.D., Idle J.R. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 1993, 53:3758-3764.
22. Boddy A.V., Yule S.M., Wyllie R., Price L., Pearson A.D., Idle J.R. Comparison of continuous infusion and bolus administration of ifosfamide in children. Eur J Cancer 1995, 31A:785-790.
23. Boddy A.V., Yule S.M., Wyllie R., Price L., Pearson A.D., Idle J.R. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 1996, 38:147-154.
24. Boddy A.V., Cole M., Pearson A.D., Idle J.R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995, 36:53-60.
25. Boddy A.V., Proctor M., Simmonds D., Lind M.J., Idle J.R. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 1995, 31A:69-76.
26. Martino R., Crasnier F., Chouini-Lalanne N., Gilard V., Niemeyer U., De Forni M., et al. A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy. J Pharmacol Exp Ther 1992, 260:1133-1144.
27. Brock N., Pohl J., Stekar J. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds. J Cancer Res Clin Oncol 1981, 100:311-320.
28. Brock N., Stekar J., Pohl J., Niemeyer U., Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 1979, 29:659-661.
29. Aeschlimann C., Cerny T., Kupfer A. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 1996, 24:1336-1339.
30. Kupfer A., Aeschlimann C., Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol 1996, 50:249-252.
31. Dubourg L., Michoudet C., Cochat P., Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J Am Soc Nephrol 2001, 12:1615-1623.
32. Loqueviel C., Malet-Martino M., Martino R. A 13C NMR study of 2-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism. Cell Mol Biol (Noisy-le-grand) 1997, 43:773-782.
33. Cheung C., Gonzalez F.J. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008, 327:288-299.
34. Chen C., Ma X., Malfatti M.A., Krausz K.W., Kimura S., Felton J.S., et al. A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem Res Toxicol 2007, 20:531-542.
35. Ma X., Chen C., Krausz K.W., Idle J.R., Gonzalez F.J. A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology 2008, 149:1869-1879.
36. Chen C., Meng L., Ma X., Krausz K.W., Pommier Y., Idle J.R., et al. Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 2006, 318:1330-1342.
37. Chen C., Krausz K.W., Idle J.R., Gonzalez F.J. Identification of novel toxicity-associated metabolites by metabolomics and mass isotopomer analysis of acetaminophen metabolism in wild-type and Cyp2e1-null mice. J Biol Chem 2008, 283:4543-4559.
38. Giri S., Idle J.R., Chen C., Zabriskie T.M., Krausz K.W., Gonzalez F.J. A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol 2006, 19:818-827.
39. Giri S., Krausz K.W., Idle J.R., Gonzalez F.J. The metabolomics of (+/-)-arecoline 1-oxide in the mouse and its formation by human flavin-containing monooxygenases. Biochem Pharmacol 2007, 73:561-573.
40. Patterson A.D., Gonzalez F.J., Idle J.R. Xenobiotic metabolism: a view through the metabolometer. Chem Res Toxicol 2010, doi: 10.1021/tx100020p.
41. Wiklund S., Johansson E., Sjostrom L., Mellerowicz E.J., Edlund U., Shockcor J.P., et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem 2008, 80:115-122.
42. Zhang H., Zhang D., Ray K., Zhu M. Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J Mass Spectrom 2009, 44:999-1016.
43. Zhang J., Tian Q., Yung Chan S., Chuen Li S., Zhou S., Duan W., et al. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005, 37:611-703.
44. Joqueviel C., Martino R., Gilard V., Malet-Martino M., Canal P., Niemeyer U. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab Dispos 1998, 26:418-428.
45. Steventon G.B. Diurnal variation in the metabolism of S-carboxymethyl-l-cysteine in humans. Drug Metab Dispos 1999, 27:1092-1097.
46. Chatton J.Y., Idle J.R., Vagbo C.B., Magistretti P.J. Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons. J Pharmacol Exp Ther 2001, 299:1161-1168.
47. Lerch S., Kupfer A., Idle J.R., Lauterburg B.H. Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy. Toxicol Lett 2006, 161:188-194.
48. Visarius T.M., Bahler H., Kupfer A., Cerny T., Lauterburg B.H. Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab Dispos 1998, 26:193-196.
49. Foxall P.J., Singer J.M., Hartley J.M., Neild G.H., Lapsley M., Nicholson J.K., et al. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. Clin Cancer Res 1997, 3:1507-1518.
50. Springate J.E. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1997, 17:75-79.
51. Woodland C., Ito S., Granvil C.P., Wainer I.W., Klein J., Koren G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000, 68:109-117.
52. Dirven H.A., van Ommen B., van Bladeren P.J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994, 54:6215-6220.
53. Rauen H.M., Norpoth K. High tension electrophoretic studies on metabolites of N,N-bis(2-chlorethyl)-N',O-propylenephosphoric acid ester-diamide from the serum of rats. Arzneimittelforschung 1967, 17:599-602.
54. Norpoth K., Addicks H.W., Witting U., Muller G., Raidt H. Quantitative determination of cyclophosphamide, ifosfamide, and trofosfamide and their stable metabolites on TLC-plates with the aid of 4-pyridine-aldehyde-2-benzothiazolyl-hydrazone (PBH) (author's transl). Arzneimittelforschung 1975, 25:1331-1336.
55. Cox P.J., Levin L. Novel metabolic products of cyclophosphamide in human urine. Biochem Pharmacol 1975, 24:1233-1235.
56. Alarcon R.A. Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat Rep 1976, 60:327-335.
57. Voelcker G., Wagner T., Hohorst H.J. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo. Cancer Treat Rep 1976, 60:415-422.
58. Jardine I., Fenselau C., Appler M., Kan M.N., Brundrett R.B., Colvin M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res 1978, 38:408-415.
59. Chan K.K., Hong S.C., Watson E., Deng S.K. Identification of new metabolites of phosphoramide and nor-nitrogen mustards and cyclophosphamide in rat urine using ion cluster techniques. Biomed Environ Mass Spectrom 1986, 13:145-154.
60. Hadidi A.H., Coulter C.E., Idle J.R. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res 1988, 48:5167-5171.
61. Hadidi A.H., Idle J.R. Combined thin-layer chromatography-photography-densitometry for the quantitation of cyclophosphamide and its four principal urinary metabolites. J Chromatogr 1988, 427:121-130.
62. Boddy A.V., Idle J.R. Combined thin-layer chromatography-photography-densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal fluid and plasma. J Chromatogr 1992, 575:137-142.
63. Fraiser L., Kehrer J.P. Murine strain differences in metabolism and bladder toxicity of cyclophosphamide. Toxicology 1992, 75:257-272.
64. Wang J.J., Chan K.K. Analysis of ifosfamide, 4-hydroxyifosfamide, N2-dechloroethylifosfamide, N3-dechloroethylifosfamide and iphosphoramide mustard in plasma by gas chromatography-mass spectrometry. J Chromatogr B Biomed Appl 1995, 674:205-217.
65. Yule S.M., Boddy A.V., Cole M., Price L., Wyllie R., Tasso M.J., et al. Cyclophosphamide metabolism in children. Cancer Res 1995, 55:803-809.
66. Linhart I., Frantik E., Vodickova L., Vosmanska M., Smejkal J., Mitera J. Biotransformation of acrolein in rat: excretion of mercapturic acids after inhalation and intraperitoneal injection. Toxicol Appl Pharmacol 1996, 136:155-160.
67. Aeschlimann C., Kupfer A., Schefer H., Cerny T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab Dispos 1998, 26:883-890.